Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

10.1016/s0140-6736(07)60982-9 ◽

2007 ◽

Vol 369 (9579) ◽

pp. 2097-2105 ◽

Author(s):

Michael G Kaplitt ◽

Andrew Feigin ◽

Chengke Tang ◽

Helen L Fitzsimons ◽

Paul Mattis ◽

...

Keyword(s):

Parkinson’S Disease ◽

Gene Therapy ◽

Parkinson's Disease ◽

Phase I ◽

Phase I Trial ◽

Adeno Associated Virus ◽

Open Label Phase

Download Full-text

Faculty Opinions recommendation of Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1087568.540634 ◽

2007 ◽

Author(s):

Robert Sapolsky

Keyword(s):

Parkinson’S Disease ◽

Gene Therapy ◽

Parkinson's Disease ◽

Phase I ◽

Phase I Trial ◽

Adeno Associated Virus ◽

Open Label Phase

Download Full-text

Faculty Opinions recommendation of Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1087568.543850 ◽

2007 ◽

Author(s):

Nanna Finnerup

Keyword(s):

Parkinson’S Disease ◽

Gene Therapy ◽

Parkinson's Disease ◽

Phase I ◽

Phase I Trial ◽

Adeno Associated Virus ◽

Open Label Phase

Download Full-text

429. Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease: Results from an Open-Label, Phase I Trial

Molecular Therapy ◽

10.1016/s1525-0016(16)38787-1 ◽

2009 ◽

Vol 17 ◽

pp. S168

Keyword(s):

Parkinson’S Disease ◽

Gene Therapy ◽

Parkinson's Disease ◽

Phase I ◽

Phase I Trial ◽

Acid Decarboxylase ◽

Amino Acid Decarboxylase ◽

Open Label Phase

Download Full-text

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

The Lancet Neurology ◽

10.1016/s1474-4422(08)70065-6 ◽

2008 ◽

Vol 7 (5) ◽

pp. 400-408 ◽

Author(s):

William J Marks ◽

Jill L Ostrem ◽

Leonard Verhagen ◽

Philip A Starr ◽

Paul S Larson ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Phase I ◽

Phase I Trial ◽

Idiopathic Parkinson’S Disease ◽

Adeno Associated Virus ◽

Idiopathic Parkinson's Disease ◽

Virus Serotype ◽

Open Label Phase

Download Full-text

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial

10.1016/s0140-6736(13)61939-x ◽

2014 ◽

Vol 383 (9923) ◽

pp. 1138-1146 ◽

Author(s):

Stéphane Palfi ◽

Jean Marc Gurruchaga ◽

G Scott Ralph ◽

Helene Lepetit ◽

Sonia Lavisse ◽

...

Keyword(s):

Parkinson’S Disease ◽

Gene Therapy ◽

Parkinson's Disease ◽

Dose Escalation ◽

Lentiviral Vector ◽

Phase 1 ◽

Open Label Phase

Download Full-text

Faculty Opinions recommendation of Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718235629.793491568 ◽

2014 ◽

Author(s):

Joseph Jankovic ◽

Mary Ann Thenganatt

Keyword(s):

Parkinson’S Disease ◽

Gene Therapy ◽

Parkinson's Disease ◽

Dose Escalation ◽

Lentiviral Vector ◽

Phase 1 ◽

Open Label Phase

Download Full-text

Faculty Opinions recommendation of Safety and tolerability of intrathecal delivery of autologous bone marrow nucleated cells in children with cerebral palsy: an open-label phase I trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718318264.793494245 ◽

2014 ◽

Author(s):

Joanne Kurtzberg ◽

Jessica Sun

Keyword(s):

Bone Marrow ◽

Cerebral Palsy ◽

Phase I ◽

Phase I Trial ◽

Autologous Bone Marrow ◽

Children With Cerebral Palsy ◽

Open Label Phase ◽

Autologous Bone

Download Full-text

An open-label, phase I trial of transplantation therapy with allogeneic adipose tissue-derived multilineage progenitor cells in homozygous familial hypercholesterolemia patients

Atherosclerosis ◽

10.1016/j.atherosclerosis.2015.04.389 ◽

2015 ◽

Vol 241 (1) ◽

pp. e111

Author(s):

M. Koseki ◽

S. Yamashita

Keyword(s):

Adipose Tissue ◽

Phase I ◽

Progenitor Cells ◽

Familial Hypercholesterolemia ◽

Phase I Trial ◽

Homozygous Familial Hypercholesterolemia ◽

Open Label Phase ◽

Transplantation Therapy

Download Full-text

P2.205 A phase I/II clinical trial to evaluate the safety and efflcacy of ProSavin®, a gene therapy approach for Parkinson's disease

Parkinsonism & Related Disorders ◽

10.1016/s1353-8020(09)70556-5 ◽

2009 ◽

Vol 15 ◽

pp. S145

Author(s):

B. Jarraya ◽

H. Lepetit ◽

S. Ralph ◽

S. Boulet ◽

C. Jan ◽

...

Keyword(s):

Parkinson’S Disease ◽

Clinical Trial ◽

Gene Therapy ◽

Parkinson's Disease ◽

Phase I ◽

Therapy Approach ◽

Gene Therapy Approach

Download Full-text

Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer

Investigational New Drugs ◽

10.1007/s10637-008-9182-8 ◽

2008 ◽

Vol 27 (3) ◽

pp. 253-261 ◽

Author(s):

Michael Michael ◽

Peter Gibbs ◽

Robert Smith ◽

Alex Godwood ◽

Stuart Oliver ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase I ◽

Phase I Trial ◽

Advanced Colorectal Cancer ◽

Open Label Phase

Download Full-text